Sign in to view content

Assessment of Central Subfield Thickness Fluctuations and Impact on Vision in Archway Phase 3 Trial of the Port Delivery System With Ranibizumab (PDS)

Chirag D. Jhaveri, MD, FASRS

Video
Published 2021

Related

Economic Benefit of Higher Durability Anti-VEGF Agents in the Treatment of Neovascular Macular Degeneration
Sabin Dang, MD
Annual Meeting Talks
2023
Key Pearls of the Refill-Exchange Procedure for the Port Delivery System With Ranibizumab (PDS)
Jordan M. Graff, MD, FACS
Annual Meeting Talks
2021
Analysis of Retinal Fluid and Vision Outcomes in the Archway Phase 3 Trial of the Port Delivery System With Ranibizumab (PDS) in Patients With nAMD
Arshad M. Khanani, MD, MA, FASRS
Annual Meeting Talks
2021

Category: AMD-Neovascular

See more